Nutra Pharma Corp (NPHC) Net Margin (2010 - 2026)

Nutra Pharma has disclosed Net Margin across 17 years of filings, most recently posting 11458.0% for Q2 2026.

• In Q2 2026, Net Margin fell 1189521.0% year-over-year to 11458.0%; the TTM figure through Jun 2026 stood at 3370.64% (down 288647.0% YoY), while the FY2025 annual figure was 627.86%, down 21550.0% from the prior year.
• Net Margin came in at 11458.0% for Q2 2026 at Nutra Pharma, down from 1687.13% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 26720.62% in Q1 2022 to a low of 11458.0% in Q2 2026.
• Average Net Margin over 5 years is 336.71%, with a median of 624.79% recorded in 2023.
• The largest YoY upside for Net Margin was 18117849 bps in 2022 against a maximum downside of 6748243 bps in 2022.
• Over 5 years, Net Margin stood at 4178.95% in 2022, then tumbled by 112 bps to 516.81% in 2023, then soared by 45 bps to 282.03% in 2024, then tumbled by 500 bps to 1692.51% in 2025, then tumbled by 577 bps to 11458.0% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 11458.0% in Q2 2026, 1687.13% in Q1 2026, and 1692.51% in Q4 2025.